These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 38587651
1. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center. Mayer M, Wolber P, Prinz J, Jansen L, Esser J, Shabli S, Quaas A, Klußmann JP, Sharma SJ, Nachtsheim L, Arolt C. Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3779-3789. PubMed ID: 38587651 [Abstract] [Full Text] [Related]
8. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF, PALGA Group, Jonker MA, Flucke UE, van Herpen CML. Int J Cancer; 2018 Aug 15; 143(4):758-766. PubMed ID: 29492965 [Abstract] [Full Text] [Related]
9. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK. Clin Cancer Res; 2014 Dec 15; 20(24):6570-81. PubMed ID: 25316813 [Abstract] [Full Text] [Related]
13. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit DB, Berger MF, Schultz ND, Reis-Filho JS, Chan TA, Morris LG. Clin Cancer Res; 2016 Sep 15; 22(18):4623-33. PubMed ID: 27103403 [Abstract] [Full Text] [Related]
15. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Sousa LG, Wang K, Torman D, Binks BJ, Rubin ML, Andersen CR, Lewis WE, Rivera MJ, Kaya D, El-Naggar AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Rodon J, Meric-Bernstam F, Lee JJ, Ferrarotto R. Cancer; 2022 Feb 01; 128(3):509-518. PubMed ID: 34661906 [Abstract] [Full Text] [Related]
16. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Mitani Y, Lin SH, Pytynia KB, Ferrarotto R, El-Naggar AK. Clin Cancer Res; 2020 Mar 01; 26(5):1175-1184. PubMed ID: 31772120 [Abstract] [Full Text] [Related]
17. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma. Liang L, Williams MD, Bell D. Head Neck Pathol; 2019 Dec 01; 13(4):529-534. PubMed ID: 30390196 [Abstract] [Full Text] [Related]
18. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast. Kusafuka K, Kawasaki T, Maeda M, Yamanegi K, Baba S, Ito Y, Inagaki H, Nakajima T. Histopathology; 2017 Jan 01; 70(2):164-173. PubMed ID: 27079821 [Abstract] [Full Text] [Related]
20. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. van Boxtel W, Verhaegh GW, van Engen-van Grunsven IA, van Strijp D, Kroeze LI, Ligtenberg MJ, van Zon HB, Hendriksen Y, Keizer D, van de Stolpe A, Schalken JA, van Herpen CM. Int J Cancer; 2020 Jun 01; 146(11):3196-3206. PubMed ID: 31745978 [Abstract] [Full Text] [Related] Page: [Next] [New Search]